NCT06820957: An ongoing trial by Children's Oncology Group
This trial is ongoing. It must report results 8 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06820957 |
|---|---|
| Title | Randomized Phase 2/3 Trial of Vincristine-Irinotecan-Regorafenib in Combination With Vincristine-Doxorubicin-Cyclophosphamide (VDC) and Ifosfamide-Etoposide (IE) in Patients With Newly Diagnosed Metastatic Ewing Sarcoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 10, 2025 |
| Completion date | June 30, 2026 |
| Required reporting date | June 30, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Oct. 21, 2026 |
| Days late | None |